If you're having trouble refilling compounded tirzepatide through Hims, it's very likely a regulatory issue, not a shipping delay — Hims discontinued its compounded semaglutide sales following FDA action, and compounded tirzepatide access has tightened industry-wide.
If your refill has stalled, compounded tirzepatide through a licensed 503A pharmacy remains a legal option for patients with a valid, individualized prescription.
If you've tried to refill compounded tirzepatide through Hims recently and hit a wall, you're not imagining it, and it's very unlikely to be a simple shipping hiccup. This traces back to a significant regulatory shift that reshaped the entire compounded GLP-1 telehealth industry, not just Hims specifically.
What Actually Happened
The FDA determined the tirzepatide shortage resolved in December 2024, followed by semaglutide in February 2025. Once a drug is off the FDA's shortage list, the legal basis that allowed widespread "essentially a copy" compounding during the shortage no longer applies to routine, cost-driven compounding — ongoing 503A compounding is limited to situations with documented individual clinical justification (such as an allergy to an inactive ingredient in the brand product), not simply lower cost or convenience. Following this shift, Hims & Hers discontinued its compounded semaglutide sales, and its compounding pharmacy partner ceased production of these medications. The regulatory pressure has continued into 2026: the FDA proposed on April 30, 2026 to permanently remove semaglutide, tirzepatide, and liraglutide from the list of substances outsourcing facilities may compound in bulk, with the agency stating it found no clinical need for that broader compounding pathway.
Why This Shows Up as a "Refill Problem"
For patients already on a compounded tirzepatide subscription, this regulatory shift often shows up as a refill that simply doesn't process, a notice that the specific product is no longer available, or a provider recommending a switch to a different option — rather than an explicit explanation of the underlying regulatory cause. It's worth understanding that this is an industry-wide compliance issue tied to the shortage resolution, not a quality or service failure specific to one company.
Compounded tirzepatide remains legally available in 2026 through licensed 503A pharmacies when there's a genuine, documented individual clinical justification for compounding rather than using the commercially available product — not merely as a lower-cost substitute. Any provider offering compounded tirzepatide should be transparent about the clinical basis for your specific prescription, and about which licensed pharmacy is preparing it.
Your Options If Your Refill Has Stalled
Contact your provider directly and ask specifically whether the issue is a supply/regulatory change rather than a shipping delay — that distinction determines what your realistic next steps are. If compounded tirzepatide is genuinely no longer available to you, options include: brand-name Zepbound or Mounjaro through insurance or manufacturer self-pay programs (LillyDirect vials commonly run $299-$449/month depending on dose), or discussing with a new provider whether an individualized clinical justification for continued compounding applies to your specific situation.
What to Do Next
- Ask your current provider directly whether this is a supply/regulatory issue
- Don't wait too long before exploring alternatives to avoid a treatment gap
- Consider brand-name self-pay pricing as a bridge if needed
- What's the clinical basis for compounding rather than using the commercial product?
- Which licensed pharmacy prepares the medication, and is it verifiable?
- How stable has their supply been through recent regulatory changes?
Questions about your
current treatment options?
Luma Health's providers can evaluate your situation and discuss appropriate options, including compounded tirzepatide at $297/month where clinically appropriate.
Get Started → Or start your free health assessmentFrequently Asked Questions
Most likely because the FDA resolved the tirzepatide shortage in December 2024, which removed the legal basis for widespread cost-driven compounding. Several telehealth providers, including Hims, subsequently discontinued compounded GLP-1 sales.
Yes, but only through licensed 503A pharmacies with a genuine, documented individual clinical justification for compounding rather than using the commercially available product — not simply as a lower-cost substitute.
The FDA proposed removing semaglutide, tirzepatide, and liraglutide from the list of substances that outsourcing facilities (503B) can compound in bulk, stating it found no clinical need for that pathway. This is a separate, additional regulatory action beyond the shortage resolution.
Brand-name Zepbound or Mounjaro through insurance or manufacturer self-pay (LillyDirect vials commonly $299-$449/month by dose), or discussing with a provider whether a documented individual clinical justification applies to your situation.
Industry-wide. The shortage resolution and subsequent FDA enforcement actions affected compounding pharmacies and telehealth providers broadly, not one company specifically.
Ask directly what the documented clinical justification is for compounding in your specific case, and verify the pharmacy's state board license independently. A provider unwilling to answer either question is a red flag.
References
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. FDA.gov. 2025. FDA.gov
- U.S. Food and Drug Administration. Human Drug Compounding and the FD&C Act. FDA.gov. FDA.gov
- GoodRx. The Tirzepatide Shortage Is Over: Here's What You Need to Know. GoodRx.com. 2026. GoodRx.com
- U.S. Food and Drug Administration. Prescribing Information for Zepbound (tirzepatide) and Mounjaro (tirzepatide). FDA.gov. 2025. FDA Drug Approvals Database